



103 RCE/PTO 09 DEC 2005

10/517275 /SB/21 (09-04)
APR 04 2006 for use through 04/01/2006 OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

	Application Number	10/517,275
	Filing Date	June 10, 2003
	First Named Inventor	Wei-Ping Min et al.
	Art Unit	
	Examiner Name	
5	Attorney Docket Number	4767-217 LAB

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		
	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	SIM & McBURNEY		
Signature			
Printed name	Dr. Lola A. Bartoszewicz		
Date	November 24, 2005	Reg. No.	43394

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature

Typed or printed name	Dr. Lola A. Bartoszewicz	Date	December 8, 2005
-----------------------	--------------------------	------	------------------

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 4 Attorney Docket Number 4767-217 LAB

Complete if Known

Application Number	10/517,275
Filing Date	June 10, 2003
First Named Inventor	Wei-Ping Min et al.
Art Unit	
Examiner Name	

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number-Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-5,199,942	April 6, 1993	Gillis	
		US-5,851,756	December 22, 1998	Steinman et al.	
		US-6,017,527	January 25, 2000	Maraskovsky et al.	
		US-6,251,665	June 26, 2001	Cezayirli et al.	
		US-6,458,585	October 1, 2002	Vachula et al.	
		US-6,475,483	November 5, 2002	Steinman et al.	
		US-6,497,876	December 24, 2002	Marashovsky et al.	
		US-6,479,286	November 12, 2002	Nelson et al.	
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cited No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		WO 99/32619	July 1, 1999	The Carnegie Institute of Washington	
		WO 01/75164	October 11, 2001	Whitehead Institute for Biomedical Research et al.	
		WO 02/44321	June 6, 2002	Maxplanck-Gesellschaft zur Förderung der Wissenschaften E.V.	

Examiner Signature		Date Considered/
--------------------	--	------------------

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet

2

of

4

Complete if Known

Application Number	10/517,275
Filing Date	June 10, 2003
First Named Inventor	Wei-Ping Min et al
Art Unit	
Examiner Name	

Attorney Docket Number 4767-217 LAB

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		AKBARI, O. et al., "Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen", <i>Nat Immunol</i> (2001) vol. 2 pp. 725-731.	
		BANCHEREAU, J. and R. Steinman, "Dendritic cells and the control of immunity", <i>Nature</i> (1998), vol. 392 pp. 245-248.	
		BELZ, G. et al., "The role of dendritic cell subsets in selection between tolerance and immunity", <i>Immunol Cell Biol</i> , (2002), Vol 80, pp. 463-468.	
		BRUMMELKAMP, T. et al., "A System for Stable Expression of Short Interfering RNAs in Mammalian Cells", <i>Science</i> , (2002), Vol 296, Issue 5567, pp. 550-553	
		BUSSIÈRE J. et al., Chapter 3: "Preclinical Safety Assessment Consideration in Vaccine Development". <i>Pharmaceutical Biotechnology</i> - Vol. 6: Vaccine Design – The Subunit and Adjuvant Approach, Edited by M. Powell and M. Newman, Published by Plenum Press, NY. (1995), pg. 61-79	
		CELLA, M. et al., "Maturation, activation, and protection of dendritic cells induced by double-stranded RNA", <i>J Exp Med.</i> , (1999), vol. 189, pp.821-829	
		CHANG, C. et al., "Tolerization of dendritic cells by T _h 1 cells: the crucial role of inhibitory receptors ILT3 and ILT4", <i>Nat Immunol</i> . Mar;3(3), (2002), pp 237-243.	
		CHICAS, A. and G. Macino., "Characteristics of post-transcriptional gene silencing", <i>EMBO Rep</i> (2001), Vol. 2, pp.992-996.	
		COGONI, C. and G. Macino., "Post-transcriptional gene silencing across kingdoms". <i>Curr Opin Genet Dev</i> , (2000), Vol.10, pp. 638-643.	
		CURIEL, T. et al., "Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity", <i>Nat Med</i> (2003), May;9(5), pp.562-567.	
		DEMANGEL, C. et al., "Autocrine IL-10 impairs dendritic cell (DC)-derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local IL-12 production", <i>Eur J Immunol</i> (2002), Vol. 32, pp. 994-1002.	
		DEMIR, G. et al., "Use of RNA interference (RNAi) to disrupt C-Kit gene expression in malignant human hematopoietic and neuroepithelial cells", <i>Blood</i> . (2000)Vol. 96 (No. 11) Part 2, pp. 378b.	
		DREWE, E. and R. Powell., "Clinically useful monoclonal antibodies in treatment", <i>J Clin Pathol</i> , (2002), Vol. 55, pp. 81-85.	
		ELBASHIR, S. et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs", <i>Methods</i> , (2002), vol. 26, pp.199-213.	
		ELBASHIR, S. et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells", <i>Nature</i> (2001), Vol. 411, pp.494-498.	
		FJOSE, A. et al., "RNA interference: mechanisms and application", <i>Biotechnol. Annu. Rev.</i> (2002) Vol. 7, pp. 31-57	
		FIRE, A. et al. "Potent and specific genetic interference by double-stranded RNA in <i>Caenorhabditis elegans</i> ", <i>Nature</i> , (1998), Vol. 391, pp. 806-811.	
		GAO, J. et al., "CD40-deficient dendritic cells producing interleukin-10, but not interleukin-12, induce T-cell hyporesponsiveness in vitro and prevent acute allograft rejection", <i>Immunology</i> , (1999), Vol. 98, pp.159-170.	
		GEWIRTZ, A., "Oligonucleotide therapeutics: clothing the emperor". <i>Curr Opin Mol Ther</i> , (1999), Vol. 1, pp. 297-306.	
		GILLIET M. et al., "Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells", <i>J. Exp. Med.</i> Mar 18;195(6), (2002), pp.695-704.	
		GORCZYNSKI, R. et al. "Regulation of gene expression of murine MD-1 regulates subsequent T cell activation and cytokine production", <i>J Immunol</i> (2000), Vol. 165, pp. :1925-1932.	
		HANNON, G. J., "RNA interference", <i>Nature</i> , (2002), Vol 418, pp. 244-251.	
		JONULEIT, H. et al., "Dendritic cells as a tool to induce anergic and regulatory T cells. Trends", <i>Immunol</i> , (2001), Vol. 22, pp. 394-400.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number	10/517,275
Filing Date	June 10, 2003
First Named Inventor	Wei-Ping Min et al
Art Unit	
Examiner Name	

Sheet

3

of

4

Attorney Docket Number

4767-217 LAB

	KAWAHATA, K. et al., "Peripheral Tolerance to a Nuclear Autoantigen: Dendritic Cells Expressing a Nuclear Autoantigen Lead to Persistent Anergic State of CD4+ Autoreactive T Cells After Proliferation", <i>J Immunol</i> Feb 1;168(3), (2002), pp. 1103-12.	
	KELLEHER, P. and S. Knight. "IL-12 increases CD80 expression and the stimulatory capacity of bone marrow-derived dendritic cells". <i>Int Immunol</i> , (1998), Vol.10, pp.749-755	
	KHANNA, A. et al, "Effects of liver-derived dendritic cell progenitors on Th1- and Th2-like cytokine responses in vitro and in vivo", <i>J Immunol</i> , .(2000),Vol. 164, pp. 1346-1354.	
	KOHKA, H. et al., , "Involvement of interleukin-18 (IL-18) in mixed lymphocyte reactions (MLR)", <i>J Interferon Cytokine Res.</i> , (1999), Vol 19, pp. 1053-1057.	
	LAMBERTON, J. and A. Christian, "Varying the Nucleic Acid Composition of siRNA Molecules Dramatically Varies the Duration and Degree of Gene Silencing", <i>Mol. Biotechnol.</i> (2003), Jun 24(2), pp. 111-120.	
	LEVY, D. and A. Garcia-Sastre, "The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion", <i>Cytokine Growth Factor Rev.</i> , (2001), Vol.12, pp. 143-156.	
	LIMMER, A. and P. Knolle, "Liver Sinusoidal Endothelial Cells: a new Type of Organ-Resident Antigen-Presenting Cell", <i>Arch Immunol Ther Exp (Warsz) Suppl.</i> , (2001), Vol. 1, pp. S7-11.	
	LIU, L. et al. 1998. Induction of Th2 cell differentiation in the primary immune response: dendritic cells isolated from adherent cell culture treated with IL-10 prime naive CD4+ T cells to secrete IL-4. <i>Int Immunol</i> 10:1017	
	LU, L. and A. Thomson, "Manipulation of dendritic cells for tolerance induction in transplantation and autoimmune disease", <i>Transplantation</i> , (2002), Vol. 73, Pp.S19-22	
	LUNDQVIST, A. et al., "Nonviral and viral gene transfer into different subsets of human dendritic cells yield comparable efficiency of transfection", <i>J Immunother</i> , (2002), Vol. 25, pp.445-454.	
	MAHNKE, K. et al., "Immature, but not inactive: the tolerogenic function of immature dendritic cells", <i>Immunol Cell Biol</i> , (2002), Vol. 80, pp. 477-483.	
	MALDONADO-LOPEZ, R. and M. Moser, "Dendritic cell subsets and the regulation of Th1/Th2 responses". <i>Semin Immunol</i> , (2001), Vol. 13, pp.275-282.	
	MARTINEZ, J. et al., "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi", <i>Cell</i> , (2002), Vol. 110, pp. 563-574.	
	McGUIRK, P. et al., "Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by <i>Bordetella pertussis</i> " <i>J Exp Med.</i> , (2002), Vol. 195, pp.221-231	
	McMANUS, M. et al., "Small Interfering RNA-Mediated Gene Silencing in T Lymphocytes", <i>J Immunol</i> , (2002), Vol. 169, pp. 5754-5760.	
	MIN, W. et al., "Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance", <i>J Immunol In Press</i> , (2002), pp. 1304-1312.	
	MIN, W. et al., "Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival", <i>J Immunol</i> , (2000), Vol. 164, pp. 161-167.	
	MOREL, P. and M. Feili-Hariri, "How do dendritic cells prevent autoimmunity?" <i>Trends Immunol</i> , (2001), Vol. 22, pp.546-547.	
	MORITA, Y. et al., "Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis", <i>J Clin Invest</i> , (2001), Vol. 107, pp.1275-1284.	
	MORRIS, M. et al., "A new peptide vector for efficient delivery of oligonucleotides into mammalian cells", <i>Nucleic Acid Res.</i> , (1997), Jul 15;25(14), pp. 2730-2736	
	MOSS, E., "RNA interference: it's a small RNA world". <i>Curr Biol</i> , (2001), Vol 11, pp. R772-R775.	
	O'GARRA, A. et al., "The role of macrophage- and dendritic cell-derived IL12 in Th1 phenotype development", <i>Res Immunol</i> , (1995), Vol. 146, pp.466-472.	
	PARDOLL, D. M., "Cancer vaccines", <i>Nat Med</i> , (1998), Vol. 4, pp. 525-531.	
	PEREZ, V. et al., "Endothelial Antigen Presentation: Stimulation of Previously Activated but Not Naïve TCR-Transgenic Mouse T Cells", <i>Cell Immunol</i> . (1998), Oct 10;189(1), pp.31-40.	
	PICCOTTI, J. et al., "Alloantigen-reactive Th1 development in IL-12-deficient mice", <i>J Immunol</i> , (1998), Vol. 160, pp.1132-1138.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

				<i>Complete if Known</i>
Sheet 4 of 4				Application Number 10/517,275
				Filing Date June 10, 2003
				First Named Inventor Wei-Ping Min et al
				Art Unit
				Examiner Name
				Attorney Docket Number 4767-217 LAB

	PIEMONTI, L. et al., "Vitamin D ₃ Affects Differentiation, Maturation, and Function of Human Monocyte-Derived Dendritic Cells", <i>J. Immunol.</i> (2000), May 1;164(9), pp.4443-4451	
	PRUD'HOMME, G. J., "Gene therapy of autoimmune diseases with vectors encoding regulatory cytokines or inflammatory cytokine inhibitors", <i>J Gene Med.</i> , (2000), Vol. 2, pp 222-232.	
	RONCARLO, M. et al., "Differentiation of T Regulatory Cells by Immature Dendritic Cells", <i>J. Exp. Med.</i> (2001), Jan 15; 193(2), pp.F5-F9.	
	SELVAM M.P. et al., "Inhibition of HIV replication by immunoliposomal antisense oligonucleotide", <i>Antiviral Res.</i> (1996), Dec 33(1), pp.11-20	
	SIMEONI F. et al., "Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells", <i>Nucleic Acids Res</i> Jun 1;31(11)(2003), pp.2717-2724.	
	TADMORI, W. et al., "Suppression of the allogeneic response by human IL-10: a critical role for suppression of a synergy between IL-2 and TNF-alpha", <i>Cytokine</i> (1994), Vol. 6, pp.462-471.	
	TOURKOVA, I. et al., "Mechanisms of dendritic cell-induced T cell proliferation in the primary MLR assay", <i>Immunol Lett.</i> , (2001), Vol. 78, pp. 75-82.	
	TRINCHIERI, G., "Interleukin-12: a cytokine at the interface of inflammation and immunity", <i>Adv Immunol.</i> , (1998), Vol. 70, pp.83-243	
	TUSCHL, T., "Expanding small RNA interference". <i>Nat Biotechnol.</i> , (2002), Vol.20, pp.446-448.	
	TUSCHL, T. et al., "Selection <i>in vitro</i> of novel ribozymes from a partially randomized U2 and U6 snRNA library", <i>EMBO J.</i> , (1998), Vol. 17, pp.2637-2650.	
	TUSCHL, T. et al., "Targeted mRNA degradation by double-stranded RNA <i>in vitro</i> ". <i>Genes Dev.</i> (1999), Vol. 13, pp. 3191-3197	
	VAN DE WETERING, M. et al., "Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector", <i>EMBO reports</i> 4(6) (2003), pp.609-615	
	VERHASSELT, V. et al., "N-Acetyl-L-Cysteine Inhibits Primary Human T Cell Responses at the Dendritic Cell Level: Association with NF- κ B Inhibition", <i>J. Immunol.</i> Mar 1;162(5) (1999), pp. 2569-2574.	
	VOGEL F. and M. Powell, "Chapter 7: A Compendium of Vaccine Adjuvants and Excipients. Pharmaceutical Biotechnology" - Vol. 6: <i>Vaccine Design – The Subunit and Adjuvant Approach</i> , Edited by M. Powell and M. Newman, Published by Plenum Press, NY., (1995), pg. 141-228	
	WANG, X. et al., "Interleukin-10 modulation of alloreactivity and graft-versus-host reactions". <i>Transplantation</i> , (2002), Vol 74, pp. 772.	
	YOSHIMURA, S. et al., "Role of NF κ B in antigen presentation and development of regulatory T cells elucidated by treatment of dendritic cells with the proteasome inhibitor PSI", <i>Eur J. Immunol.</i> , (2001), Jun;31(6), pp. 1883-93.	
	ZHU, X et al., "Effects of 15-deoxyspergualin <i>in vitro</i> and <i>in vivo</i> on cytokine gene expression", <i>Transplantation</i> (1994), Vol. 58, pp.1104-1109.	
	NAIR et al., US 2002/0018769, published February 14, 2002	
	GEWIRTZ, US 2002/0173478, published November 21, 2002	
	BEACH et al., US 2002/0162126, Published October 31, 2002	
	Lin, US 2003/0104401, published June 5, 2003	